Clinical trials: Hyperphosphatemia
ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD)
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
This Phase 3 clinical trial is the pivotal study of AP301 aiming to evaluate the efficacy and safety of AP301 for controlling serum phosphorus in chronic kidney disease receiving hemodialysis and peritoneal dialysis in Chinese…
- Conditions
- ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD), Hyperphosphatemia, Hyperphosphatemia in Chronic Kidney Disease
- Trial name
- RESPOND-1 (NCT07030595)
- Testing
- AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose
- Where
- 50 sites in China
- Volunteers
- 474 people
- Sponsor
- Alebund Pharmaceuticals
Hyperphosphatemia
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
The aim of the study is: To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses； To evaluate the…
- Trial name
- NCT04440696
- Testing
- Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Grand Life Science (Liaoning) Co., Ltd.
Kidney Failure, Chronic, End-stage Renal Disease
Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
To assess the long-term safety and effectiveness of Nephoxil® for the treatment of hyperphosphatemia in patients with ESRD undergoing dialysis.
- Conditions
- Kidney Failure, Chronic, End-stage Renal Disease, Phosphorus Metabolism Disorders, Hyperphosphatemia
- Trial name
- NCT03256838
- Testing
- Ferric Citrate
- Where
- 9 sites in Taiwan
- Volunteers
- 202 people
- Sponsor
- Panion & BF Biotech Inc.
Hemodialysis, Hyperphosphatemia
Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access…
- Conditions
- Hemodialysis, Hyperphosphatemia, Cardiovascular Events
- Trial name
- NCT01755078
- Testing
- Sevelamer HCl, Calcium-based phosphate binder
- Volunteers
- 166 people
- Sponsor
- Chugai Pharma Taiwan
Hyperphosphatemia, Kidney Failure
EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)
The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.
- Trial name
- NCT00211978
- Testing
- calcium acetate
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Nabi Biopharmaceuticals
Hyperphosphatemia
Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients
The purpose of this study is to assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (lanthanum carbonate) in patients with hyperphosphatemia undergoing continuous ambulatory peritoneal dialysis.
- Trial name
- NCT01518387
- Testing
- Lanthanum Carbonate (BAY77-1931)
- Where
- 11 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Bayer
Kidney Failure, Chronic
Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
The purpose of this clinical study is to compare the effects of Genz-644470 with the effects of placebo and sevelamer carbonate (Renvela®) on the reduction of serum phosphorus in hyperphosphatemic chronic kidney disease…
- Trial name
- LEAP (NCT00853242)
- Testing
- Genz-644470, Sevelamer carbonate
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 349 people
- Sponsor
- Genzyme, a Sanofi Company
Hyperphosphatemia Patients on Hemodialysis
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
- Trial name
- NCT07285304
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia
Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To evaluate the efficacy of KHK7791 in combination with phosphate binders by comparing changes in serum phosphorus levels between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 30 mg in…
- Trial name
- NCT04766398
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 169 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia Related to Chronic Kidney Disease
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
- Trial name
- NCT04523727
- Testing
- ferric citrate
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Keryx Biopharmaceuticals
Hyperphosphatemia, Chronic Kidney Disease
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced.
- Trial name
- OsvaRenNEW (NCT02027662)
- Testing
- Osvaren Granules, Osvaren film-coated tablets
- Where
- 11 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Chronic Kidney Disease, Hyperphosphatemia
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
This is a phase III multi-centre study in three periods: the first period is a phosphate binder washout for 4 weeks, the second period is an open-label, randomised, parallel group, flexible dose, the third period is a…
- Trial name
- NCT00416520
- Testing
- MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®), Another phosphate binder (Sevelamer)
- Where
- 68 sites in Australia, Austria and 9 more
- Volunteers
- 336 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Disease, Dialysis
Long-term Extension Study of MCI-196
The Primary Objectives of this study are to assess the long-term efficacy of treatment with colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of treatment with colestilan (MCI-196) (including…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01814917
- Testing
- colestilan, CBPB
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Tanabe Pharma Corporation
Chronic Kidney Failure
An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate
Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at the safety of fermagate over longer periods of time.
- Trial name
- ALCON (NCT00358722)
- Testing
- Fermagate
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Ineos Healthcare Limited
End Stage Renal Disease, Chronic Kidney Disease
Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia
The primary objectives of this study are the following: 1. To demonstrate that AMG 223 will produce a statistically significant reduction in serum phosphorus compared with placebo over a 3 week treatment period in subjects with…
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease, Hyperphosphatemic, Kidney Disease
- Trial name
- NCT00530114
- Testing
- AMG 223
- Volunteers
- 167 people
- Sponsor
- Amgen
Hyperphosphatemia
Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate
To assess the effect on reduction of serum phosphate and the safety of BAY77-1931 (Lanthanum Carbonate) in patients with hyperphosphatemia undergoing hemodialysis in a randomized, double-blind, parallel group study in comparison…
- Trial name
- NCT01514851
- Testing
- Lanthanum carbonate (BAY77-1931), Calcium carbonate
- Where
- 31 sites in Japan
- Volunteers
- 259 people
- Sponsor
- Bayer
Hyperphosphatemia, Chronic Kidney Disease
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
This study will compare placebo to 4 different doses of SBR759 to assess the phosphate lowering efficacy in dialysis patients.
- Trial name
- SBR759 (NCT01069692)
- Testing
- SBR759A
- Where
- 9 sites in Belgium, Italy
- Volunteers
- 115 people
- Sponsor
- Novartis
Hyperphosphatemia
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients…
- Trial name
- NCT00567723
- Where
- 199 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Shire
Hyperphosphatemia, End Stage Renal Disease
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP >2.5 and ≤4.5 mg/dL) in patients with…
- Trial name
- NORMALIZE (NCT03988920)
- Testing
- Tenapanor, Sevelamer Carbonate
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Ardelyx
Hyperphosphatemia
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat…
- Trial name
- NCT03427125
- Testing
- Tenapanor, Sevelamer Carbonate
- Where
- 2 sites in United States
- Volunteers
- 1,559 people
- Sponsor
- Ardelyx